A concept-stage program exploring modular, cartridge-based viral testing workflows, AI-assisted result interpretation, and connected epidemiological surveillance — designed for decentralised deployment in future viral outbreak response.
The problem we are addressing
Viral respiratory and systemic infections collectively represent the largest infectious disease burden in human history. COVID-19 demonstrated at catastrophic scale what had been known for decades: the absence of fast, distributed, affordable viral diagnostic infrastructure is not merely a public health inconvenience — it is an existential vulnerability.
Viral respiratory infections remain one of the largest global causes of death — a burden that disproportionately falls on low-resource settings with the weakest diagnostic infrastructure.
Our research approach
ViroSnap is exploring a modular cartridge architecture in which the complex, chemically intensive steps of viral nucleic acid amplification are pre-integrated into a sealed, room-temperature-stable cartridge — eliminating operator handling of reagents and cold chain dependency. The concept explores a cartridge reader that performs only optical detection and AI-assisted interpretation, with all analytical chemistry self-contained in the cartridge. The reader is designed to be affordable enough for primary care deployment and simple enough for non-specialist operation.
The program also explores a connected epidemiological surveillance layer — anonymised, aggregate-level reporting of test volumes and result distributions to a public health monitoring platform — designed to enable earlier outbreak signal detection without compromising individual privacy.
A central open research question concerns nucleic-acid amplification chemistry performance in a room-temperature-stable cartridge format.
What it's for
ViroSnap is a concept-stage program exploring rapid viral detection for speed and accessibility at the point of need — intended to be fast, simple, and suited to field use.
Intended deployment
A patient presents with respiratory symptoms in a crowded clinic. ViroSnap is designed to support rapid viral pathway triage before unnecessary antibiotics or delayed isolation decisions become the default.
When symptoms appear in a dense community setting, a small rapid module could help organise early screening, referral, and public-health escalation without waiting for distant lab capacity.
Structured point-of-care outputs can become signals for public-health teams, helping local viral patterns become visible earlier than centralised reporting alone.
Why it matters
Detection that keeps ahead of spread.
One clear flow, minimal training.
Built to work outside the lab.
Accessible enough to use at scale.
Seeing it sooner changes everything after.
Questions
It is designed to detect viral signals quickly and accessibly — framed at a high level here, without revealing the underlying mechanism.
Built for field and community testing, and for the wider mission of reaching communities beyond centralised healthcare.
BIQADX is at a pre-clinical, prototype stage — ViroSnap is not currently available for commercial sale. We welcome partnership and pilot conversations.
The next outbreak will not wait for a central lab — so we are building diagnostics that meet a virus where it first appears.